Related Experiment Video

Updated: Aug 26, 2026

Use of Ultra-high Field MRI in Small Rodent Models of Polycystic Kidney Disease for In Vivo Phenotyping and Drug Monitoring
07:35

Use of Ultra-high Field MRI in Small Rodent Models of Polycystic Kidney Disease for In Vivo Phenotyping and Drug Monitoring

Published on: June 23, 2015

Protein insufficiency and linear growth restriction in phenylketonuria

Georgianne L Arnold1, Catherine J Vladutiu, Russell S Kirby

  • 1Department of Pediatrics, University of Rochester School of Medicine and Dentistry, Rochester, New York 14642, USA.

The Journal of Pediatrics
|August 17, 2002
PubMed

Insights

Protein insufficiency, indicated by low plasma prealbumin, significantly impairs linear growth in children with phenylketonuria (PKU). Maintaining prealbumin levels above 20 mg/dL is crucial for optimal PKU growth.

Area of Science:

  • Biochemistry
  • Pediatrics
  • Genetics

Background:

  • Phenylketonuria (PKU) is a genetic disorder requiring lifelong dietary management.
  • Nutritional status significantly impacts growth and development in children with chronic conditions.
  • Protein intake and specific biomarkers are critical for monitoring metabolic health in PKU.

Purpose of the Study:

  • To investigate the relationship between protein sufficiency, age, calorie intake, and phenylalanine levels in children with PKU.
  • To determine the impact of these factors on linear growth (height).

Main Methods:

  • A retrospective chart review of 38 children with early and continuously treated PKU.
  • Analysis of age, growth measurements, plasma prealbumin levels, and mean phenylalanine levels.
  • Regression modeling to assess the effect of prealbumin, age, BMI, and phenylalanine on height.

Main Results:

  • Plasma prealbumin levels below 20 mg/dL were strongly associated with a significant loss of height percentiles (45th percentile).
  • Lower prealbumin levels correlated with shorter stature and younger age.
  • While age and BMI had smaller significant effects, mean phenylalanine levels did not show a significant correlation with height.
  • A threshold of 20 mg/dL for plasma prealbumin was identified, below which linear growth was substantially impaired.

Conclusions:

  • Protein insufficiency, as indicated by plasma prealbumin levels, is a key factor in linear growth impairment in PKU.
  • Maintaining plasma prealbumin levels at or above 20 mg/dL is recommended for optimal linear growth in children with PKU.
  • This finding highlights the importance of monitoring protein status in PKU management.
Abstract

More Related Videos

A Rat Tibial Growth Plate Injury Model to Characterize Repair Mechanisms and Evaluate Growth Plate Regeneration Strategies06:53

A Rat Tibial Growth Plate Injury Model to Characterize Repair Mechanisms and Evaluate Growth Plate Regeneration Strategies

Published on: July 4, 2017

Quantifying Tissue-Specific Proteostatic Decline in Caenorhabditis elegans09:18

Quantifying Tissue-Specific Proteostatic Decline in Caenorhabditis elegans

Published on: September 7, 2021

Related Concept Videos

Nature and Nurture01:10

Nature and Nurture

Many human characteristics, like height, are shaped by both nature—in other words, by our genes—and by nurture, or our environment. For example, chronic stress during childhood inhibits the production of growth hormones and consequently reduces bone growth and height. Scientists estimate that 70-90% of variation in height is due to genetic differences among individuals, and 10-30% of variation in height is due to differences in the environments that individuals experience, such as differences...
Overview of Protein Metabolism01:21

Overview of Protein Metabolism

Proteins are broken down into amino acids during digestion. Unlike fats and carbohydrates, which are stored for later use, proteins are not. Instead, amino acids are either used to produce ATP through oxidation or contribute to the creation of new proteins for the growth and repair of the body. Any surplus amino acids from the diet are converted into glucose or triglycerides rather than excreted.
Amino acids play various roles in the body once they are absorbed into cells. They are restructured...
Inborn Errors of Metabolism01:20

Inborn Errors of Metabolism

Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
Nonlinear Pharmacokinetics: Causes of Nonlinearity01:22

Nonlinear Pharmacokinetics: Causes of Nonlinearity

Nonlinearity in drug pharmacokinetics is caused by various factors influencing how a drug is absorbed, distributed, metabolized, and excreted. Understanding these nonlinear processes is crucial for predicting drug behavior in the body and optimizing drug dosing regimens.
Nonlinear drug absorption can occur when the process is rate-limited by solubility, carrier-mediated transport systems, or saturation of the presystemic gut wall or hepatic metabolism. For instance, high doses of riboflavin...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...